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Abstract
Our previous studies have demonstrated that insulin signaling pathway has 
an important role in the pathophysiology of polycystic ovary syndrome (PCOS), 
including phosphatidylinositol 3-kinase and protein kinase B signaling, which is 
critically implicated in insulin resistance, androgen secretion, obesity, and follicular 
development. PCOS manifests as defective ovarian steroid biosynthesis and hyper-
androgenemia, and 50–70% of women with PCOS exhibit insulin resistance and are 
hyperinsulinemic, indicating that insulin resistance and hyperinsulinism may have 
an important role in the pathophysiology of PCOS. Therefore, the present article 
will review the contribution of insulin signaling pathway to the abnormal regula-
tion of follicular growth and ovulation, which can cause corresponding reproduc-
tive endocrine diseases and affect women’s reproductive health. Exploring the 
mechanism of insulin signaling pathway in PCOS will help not only to understand 
the physiology and pathology of follicular development but also to provide theoreti-
cal basis for the treatment of PCOS.
Keywords: insulin receptor substrates, protein kinase B, hypoxia-inducible factor-1, 
granulosa cells, polycystic ovary syndrome
1. Introduction
Polycystic ovary syndrome (PCOS) is an endocrine disorder syndrome with 
reproductive dysfunction and abnormal glucose metabolism, which is character-
ized by excessive androgen. It is usually accompanied by insulin resistance (IR) 
and is also a most common endocrine disorder in women of reproductive age [1]. 
Although the exact cause of PCOS is not clear, it belongs to endocrine and meta-
bolic diseases. It has been concluded that there are not only endocrine disorders 
but also metabolic abnormalities with many subtypes. Burghen firstly proposed 
that insulin resistance (IR) was involved in the pathogenesis of PCOS in 1980 [2], 
and a large number of studies have subsequently confirmed the close relationship 
between IR and PCOS. IR is a metabolic state in which the normal insulin-promoted 
glucose uptake and utilization decreased and the compensatory insulin secretion 
from tissues and organs of the body maintained the stability of blood glucose. 
Polycystic Ovarian Syndrome
2
Clinically, PCOS presents after puberty menarche, and patients have the abnormal 
glucose metabolism and the pathophysiology related to the physiological changes 
of puberty. IR is not only a normal physiological change of adolescent girls but also 
an important pathophysiological change of PCOS, that is, IR and compensatory 
hyperinsulinemia. IR is one of the important pathophysiological mechanisms in the 
occurrence and development of many PCOS and also an important cause of hyper-
androgenism and ovarian dysfunction.
2. Historical overview
The defect of insulin signaling pathway is one of the important mechanisms 
of PCOS after two centuries of research, and the historical development process 
is summarized as the following [2–11]. Achard and Thiers firstly described the 
relationship between abnormal glucose metabolism and hyperandrogenism in 
1921, and Kierland et al. believed that hyperandrogenism was related to higher 
incidence of acanthosis nigricans in female patients with diabetes mellitus in 1947. 
Kahn et al. mainly focused on the relationship between the abnormal metabolism 
in the adolescent and the hyperandrogenism, insulin resistance, and acanthosis 
nigricans in the postmenopausal women in 1976 and believed the postmenopausal 
pathogens are caused by the result of endogenous IR and the onset of adolescent 
women is caused by the mutation of insulin receptor. Until 1980, Burghen et al. 
reported that hyperinsulinemia is closely related to PCOS for the first time and 
found that hyperinsulinemia existed in PCOS patients with hyperandrogen-
ism under the basal state and after glucose stimulation compared with normal 
people of the same age and weight, suggesting IR existed and insulin was highly 
correlated with androgen levels. During the mid-1980s, Dunaif et al. found the 
follicular membrane cells of typical PCOS women proliferated significantly and 
the morphological changes of their hyperplasia were more common in PCOS 
patients with IR, suggesting that hyperinsulinemia affected ovarian morphology 
and functions.
3. Pathological changes and clinical characteristics of PCOS
Typical polycystic ovaries have stromal hypertrophy, and their volume is 2 times 
larger than that of normal ovaries. The ovaries showed bilateral sclerosing polycys-
tic degeneration and gray-white or oyster-colored [12]. There is “strand of pearls” 
appearance on USN, 2-7 mm diameter cystic follicles or large retention follicular 
cysts under the capsule. Microscopic examination showed atresia follicles increased, 
no matured follicles formed, cortical surface fibrosis, fewer cells, obvious blood 
vessels, a large number of outer follicles luteinized, and no signs of ovulation.
Menstrual disorders are the main manifestations of adolescent PCOS patients, 
with common symptoms such as hirsutism, acne, and body mass increase [12]. 
But these symptoms can also be the normal physiological manifestations after 
puberty, so most patients continue to see a doctor for infertility after several years. 
In addition to the physical changes caused by infertility and excessive androgens, 
the metabolic syndrome is more prone to cause, mainly including androgenism 
and metabolic abnormalities such as insulin, glucose, and lipid. Hypertension is 
more common in the late stage, and cardiovascular diseases such as type 2 diabetes 
mellitus and coronary heart disease are induced. Many PCOS patients often have 
IR and hyperinsulinemia as the first manifestation, followed by excessive androgen 
and reproductive dysfunction.
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4. Insulin signaling pathway
Insulin is a multifunctional protein polypeptide, which binds to its specific insu-
lin receptor and causes a series of signal amplification cascade reactions with two 
main signaling pathways; one is the phosphatidylinositol 3 kinase/protein kinase B 
(PI3K/PKB) pathway, and the other is the mitogen-activated protein kinase/extracel-
lular signal-regulated kinase (MAPK/ERK) pathway. These two signaling pathways 
are related to the self-phosphorylation of tyrosine residues in receptors, and insulin 
mainly mediates its metabolic regulation through PI3K pathway [3, 13–16].
PI3K is a kind of kinase that catalyzes phosphatidylinositol, which can be 
activated by receptor tyrosine kinase or G protein-coupled receptor. It consists of 
a catalytic subunit P110 and an inhibitory regulatory subunit p85, and it has the 
activity of lipid kinase and serine/threonine protein kinase. Many growth factors, 
such as insulin, insulin-like growth factor (IGF), platelet-derived growth factor 
(PDGF), and epidermal growth factor (EGF), bind to the corresponding recep-
tors; then tyrosine phosphorylation of the receptor itself and binding of p85 to the 
phosphorylated receptors relieve the inhibitory effect on p110, and PI3K is then 
activated. PKB is a member of the serine/threonine protein kinase family and a 
direct target protein downstream of PI3K. The phosphorylation of 308-site threo-
nine (Thr308) and 473-site serine (Ser473) required for complete activation of AKT 
depends on PI3K catalysis. After the activation of PI3K/PKB pathway, PI3K/PKB 
pathway acts on a variety of substrates, mainly regulating the material metabolism 
of cells, besides participating in cell survival and anti-apoptosis. After insulin 
binds to insulin receptor alpha subunit located in the cellular membrane, it further 
triggers tyrosine phosphorylation of beta subunit itself and further phosphorylates 
tyrosine subunit of insulin receptor substrate (IRS). p-IRS can further activate PI3K 
and then produce PIP3, a second messenger. PIP3 binds to signal proteins PKB and 
phosphoinositide dependent kinase-1 (PDK1), which contain the PH domain in 
cells, and assists PDK1 to phosphorylate 308-site threonine of PKB to make it an 
active form. Activated-PKB can promote the transfer of glucose carrier-4 (GLUT-4) 
from the cytoplasm to the envelope and promote the absorption of glucose. PKB 
then phosphorylates tuberous sclerosis complex protein 1/2 (TSC1/2) to the inactive 
state, releases its inhibition on the downstream Rheb-GDP, converts it into Rheb-
GTP, and further activates target of rapamycin complex 1 (TORC1). In addition, 
PKB also phosphorylates PRAS40, an inhibitor of mTORC1, to separate it from 
mTORC1, thereby activating mTORC1 and further exerting downstream cascade 
reactions, such as hypoxia-inducible factor-alpha (HIF-1alpha)/endothelin-2 (ET-2) 
signaling pathway-dependent ovulation [3, 13–16].
5. Insulin resistance and polycystic ovary syndrome
Insulin resistance is the defect of insulin signaling transduction, and PI3K/PKB 
signaling pathway is the main signaling pathway of insulin. In the state of IR, the 
role of PI3K signaling pathway induced by insulin stimulation decreased [3, 13]. 
The factors leading to abnormal insulin signaling transduction can be divided into 
congenital factors and acquired factors. Inborn abnormal factors, such as genetic 
defect and gene mutation, and other acquired factors, like lifestyle, obesity, and 
environment, can all cause IR by affecting PI3K/PKB signaling pathway. It was 
found that with the increase of free fatty acids in blood, they were converted into 
acy-CoA, DAG was increased, PKC was activated, serine residues in IRS-1 were 
phosphorylated, tyrosine phosphorylation in IRS-1 was decreased, PI3K activation 
was disturbed, and GLUT4 translocation to cell surface was affected, thus reducing 
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insulin-mediated glucose utilization [3, 13, 17]. The increase of free fatty acids leads 
to the increase of lipids in muscle, which in turn interferes with the use and storage 
of insulin to glucose and causes IR.
PCOS patients had no significant difference in insulin receptor quantity and 
binding ability compared with non-PCOS patients, but the phosphorylation of 
insulin receptor decreased in PCOS patients, and the maximum glucose transport 
rate stimulated by insulin decreased [11, 18]. PCOS patients often have IR and hyper-
androgenism, and IR plays a greater role in the formation of hyperandrogenism, 
while hyperandrogenism has no significant effect on the formation of IR. IR is the 
biological effect of insulin produced at physiological level in the body, which is lower 
than the actual level. The effect of insulin in promoting the absorption and utiliza-
tion of glucose by organs, tissues, and cells is reduced, that is, the insulin sensitivity 
of tissues is reduced [3, 19, 20]. Hyperinsulinemia is a marker that insulin regulates 
glycometabolism in the compensatory stage under the state of IR [3, 19, 20].
At the cellular level, IR means that insulin signaling transduction is blocked or 
weakened. This signaling from insulin receptor down to the end-mediated sub-
strates of insulin action involves many aspects of cell metabolism [3, 17–20]. Any 
link of insulin signaling impairment can lead to IR, which is closely related to the 
impairment of key molecules in the signaling of insulin, insulin receptor, insulin 
receptor substrate, PI3K, and GLUT4, specifically divided into the following three 
aspects [3, 17–20]: First, pre-receptor IR. The mutation of insulin gene leads to 
the changes of insulin primary structure and the decrease of biological activity, 
resulting in body IR. Secondly, receptor-level IR. The mutation of insulin recep-
tor gene, which cannot be cleaved into matured alpha and beta receptor subunits, 
reduced the biosynthesis of insulin receptor or the affinity between insulin receptor 
and insulin, resulting in the loss of intracellular effect of insulin and leading to 
IR. Lastly, post-receptor IR. Insulin deficiency refers to a series of abnormal meta-
bolic processes that occur when insulin binds to receptors and transmits signals to 
cells, which is the main cause of IR in PCOS patients. The physiological effect of 
insulin on glucose is the result of key enzyme activation such as insulin-dependent 
GLUT4 and G-kinase and glycogen synthase, and the defects in the structure or 
function of these enzymes can lead to IR [3, 13, 17–21]. Increased serine phosphory-
lation of insulin receptor may weaken the tyrosine kinase activity of insulin recep-
tor, which may be the mechanism of post-receptor deficiency in PCOS patients.
6. PCOS ovarian IR
It is still controversial whether PCOS is a reflection of ovarian hypersensitivity 
to insulin or whether systemic IR is localized in ovaries. The study found that PCOS 
patients secrete more androgens than normal women after insulin stimulation. In 
addition, PCOS patients with normal insulin levels were treated with insulin sensi-
tizers, and it was found that insulin levels decreased slowly and ovarian androgen 
levels also decreased [22].
6.1 Molecular mechanism of IR in the follicular membrane cells of PCOS
The most common symptoms of PCOS patients are excessive androgens in 
the ovary, especially increased testosterone production by follicular membrane 
cells. Insulin can stimulate the activity of steroid hormones in follicular theca cells 
through a variety of ways, one of which is through the MAPK pathway, which is 
still controversial; the other is through LH to induce the accumulation of cyclic 
adenosine phosphate (cAMP), which stimulates the activity of PI3K [23]. Studies 
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have shown that LH and insulin have synergistic effects on the gene expression and 
mRNA accumulation of steroid hormone acute synthesis rapid regulatory protein 
(StAR) and cytochrome P450c17 (CYP-17). The increased PKB phosphorylation 
in insulin signaling pathway promotes the production of PCOS clinical symptoms 
such as follicular cell proliferation, follicular dysplasia, or anovulation, suggesting 
that insulin induces the synthesis of steroid hormones in follicular cells, which may 
be regulated by PI3K pathway, and PKB is a downstream regulator of this pathway 
[24–26]. A special blocker (LY294002) was used to block the PI3K pathway, which 
inhibited the activation of PKB and weakened the activity of 17a-hydroxylase and 
also proved the above opinion [26].
6.2 Molecular mechanism of IR in the granulosa cells of PCOS
Insulin can increase the activity of LDL receptor transcription factors through 
intracellular mechanisms such as protein kinase A (PKA), PI3K, and MAPK signal-
ing pathways, thus promoting steroid hormone synthesis [27]. It has been found 
that after inhibiting PI3K with wortmannin, IR is produced by interfering with the 
intracellular glycometabolic signaling pathway [26]. Franks compared anovula-
tory PCOS patients with ovulatory PCOS patients and found the abnormal glucose 
metabolism in granulosa cells and the significantly impaired insulin-stimulated 
lactate production, while insulin-mediated glucose metabolism was resisted 
besides the steroid hormone secretion remaining normal. Therefore, the complex 
mechanism of insulin deficiency can also be found in the local of the ovary [28]. 
Our previous studies further found that PI3K/PKB signaling pathway was impaired 
in PCOS granulosa cells, which affected the downstream HIF-1a/ET-2-dependent 
ovulation mechanism, leading to PCOS anovulation [13, 29, 30].
7. Effects of IR on ovarian functions
Insulin can activate or inhibit ovarian hormone synthase and stimulate steroid 
hormone synthesis in ovarian cells with the species or cell specificity. Human ovarian 
matrix and follicles have insulin receptor distribution and can produce IGF and bind-
ing protein. Therefore, the ovary is one of the important target organs of insulin [7–9].
7.1 Effect of IR on the level of androgen hormone
Insulin enhances the binding ability of LH by increasing the LH receptor of 
granulosa cells; insulin acts on the pituitary gland to increase the sensitivity of 
gonadotropin-releasing hormone (GnRH); insulin inhibits the synthesis of sex 
hormone-binding protein in the liver and increases the level of free insulin [7–9]. 
PCOS patients taking insulin sensitizer can increase the binding protein in the cir-
culation and decrease the free hormone, thus alleviating hyperandrogenism caused 
by hyperinsulinemia or IR [7–9].
7.2 Effect of IR on the proliferation of granulosa cells
The proliferation and physiological function of ovarian granulosa cells are very 
important for the follicular maturation and ovulation, while FSH, IGF2, and insu-
lin are important factors to promote the proliferation of granulosa cells. In PCOS 
patients, insulin regulates the glucose uptake of ovarian granulosa cells, and the 
synthesis of lactic acid, a metabolite of glucose utilization, significantly decreases, 
resulting in the impaired insulin metabolism [7–9]. Insulin can induce IR and affect 
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the proliferation of granulosa cells in PCOS patients, and most of the PCOS patients 
are complicated with hyperinsulinemia, high insulin concentration in the follicular 
fluid. However, the proliferation of granulosa cells was inhibited, and apoptosis 
was increased. Both of them synergistically enhance the expression of LH and 
HCG receptors in granulosa cells. The granulosa cells with 50–100 μm follicles have 
acquired the function of LH receptors only in matured follicles with a diameter of 
about 20 μm during normal menstrual cycle, which makes the granulosa cells with 
lumen follicle stage prematurely luteinized and inhibits their proliferation, leading to 
follicular stagnation [7–9]. Insulin also strengthens the response of granulosa cells to 
LH, leading to the LH-like peak at the elevated level of LH, which leads to the arrest 
of granulosa cell proliferation, follicular growth arrest, and anovulation [28].
7.3 Effect of IR on the development of ovarian follicles
Intraovarian follicular development undergoes a series of physiological 
processes, such as recruitment, selection, dominance, and ovulation. The basic 
manifestations of follicular dysplasia in PCOS patients are excessive follicular 
recruitment, blocked follicular selection and dominance, follicular stagnation, and 
anovulation [7–9]. Hyperinsulinemia in PCOS patients increases the sensitivity of 
preantral follicles to FSH, leading to excessive follicular recruitment, androgen syn-
thesis in thecal cells, and conversion to estradiol. Furthermore, estradiol decreased 
the secretion of pituitary FSH due to negative feedback regulation, and the follicles 
lacked FSH stimulation and grew slowly, leading to the accumulation of preantral 
follicles and small sinusoidal follicles. The immaturity of follicles resulted in the 
accumulation of a large number of sinusoidal follicles and the formation of a unique 
polycystic ovary [31, 32]. Insulin is also one of the most powerful factors affecting 
plasma plasminogen activator inhibitor-1 (PAI-1). Hyperinsulinemia causes the 
excessive PAI-1 production in the liver and inhibits the ovulation by inhibiting the 
conversion of plasminogen to plasmin. The effects of hyperinsulinemia and IGF-2 
on ovarian primordial follicles were continuously activated and finally formed the 
characteristic ovarian morphological changes of PCOS [33, 34].
7.4 Effect of IR on the signaling of ovarian PI3K
In the IR state, the decrease of PI3K signaling induced by insulin leads to the 
abnormal insulin signaling transduction. PI3K signaling is mainly related to the 
regulation of insulin on glucose metabolism. The signal molecule downstream of IRS 
is the key protein for insulin signaling to regulate the glucose metabolism. Activated 
PI3K, on the one hand, triggers vesicles rich in GLUT4 to translocate to the cell surface 
through the form of exocytosis from the endokaryon via Golgi apparatus, increases 
GLUT4 on the cell surface, and regulates the uptake of glucose by myocytes, adipo-
cytes, and hepatocytes. On the other hand, activated PI3K inhibits gluconeogenesis by 
inhibiting enol pyruvate carboxykinase and ultimately increases the utilization of glu-
cose and glycogen [7–9, 28]. Our previous studies have clearly demonstrated that the 
mechanism of IR in PCOS ovaries is related to post-insulin receptor signaling disorder 
[13, 29, 30]. At the same time, IR is also a key link in the pathogenesis of PCOS, so the 
causal relationship between PCOS and IR is still unclear.
8. Conclusion
PCOS is a disease involving many factors such as heredity and environment, 
and IR plays an important role in the development of PCOS. After insulin binds 
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to receptors, it exerts its biological effects through a series of signaling pathways. 
Obstacles in any link of the pathways can lead to the signaling disorders and cause 
IR. Compensatory hyperinsulinemia and IR are considered to be the pathologi-
cal basis of abnormal glucose metabolism and reproductive dysfunction in PCOS 
patients. Although the signaling pathway of insulin and its mechanism during the 
occurrence and development of insulin resistance are still poorly understood, PI3K/
PKB pathway, as the main signal pathway of insulin, is involved in the metabolism 
of glucose and lipid in vivo. Further study about the regulatory mechanism of PI3K/
PKB pathway and the interaction between the molecule and targeted molecule is 
needed and has high clinical value and application prospects to develop PI3K/Akt 
signaling pathway-specific drugs as a new target of IR therapy. At the same time, 
using modern molecular biology technology to comprehensively understand insulin 
signaling pathway and in-depth study of IR molecular mechanism of PCOS can 
provide a solid theoretical basis for clinical diagnosis and treatment.
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